Generex Biotechnology Raises $2.5 Million Through Private Placement
Generex is required to register for resale the shares issued in the private placement and the shares issuable upon exercise of the warrants no later than April 4, 2004. Pursuant to the terms of an Additional Investment Right, the investors have the right to purchase up to the same number of shares and warrants, at the same price, within sixty (60) days after the effectiveness of the registration statement.
"We believe this additional commitment from our existing shareholders represents another strong endorsement of Generex's Oralin(TM) technology, our upcoming clinical trials and the overall direction of the company," said Anna E. Gluskin, President & Chief Executive Officer of Generex. "This commitment will help us fund our upcoming clinical activities and help us to establish additional strategic relationships to realize opportunities to further develop our promising technologies."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.